Sign In
Buy NXTC
$4.15
-0.89 (-17.59%)
At Close: Jul 31, 2026
Critical Comparison: Sarepta Therapeutics (NASDAQ:SRPT) versus NextCure (NASDAQ:NXTC)
05:44am, Sunday, 29'th Mar 2020
Sarepta Therapeutics (NASDAQ:SRPT) and NextCure (NASDAQ:NXTC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuat
Why You Shouldn't Bet Against NextCure (NXTC) Stock
12:52pm, Thursday, 26'th Mar 2020
NextCure (NXTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Blair likes Incyte in premarket analyst action
11:53am, Tuesday, 24'th Mar 2020
Compugen (NASDAQ:CGEN) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up 9% premarket.Incyte (NASDAQ:INCY) resumed with Outperform rating at William Blair. Shares u
NextCure (NXTC) Gets a Buy Rating from Needham
03:16pm, Friday, 13'th Mar 2020
Needham analyst Chad Messer reiterated a Buy rating on NextCure (NXTC) today and set a price target of $72.00. The company's shares closed last Monday at
NextCure (NXTC) Gets a Buy Rating from Needham
03:16pm, Friday, 13'th Mar 2020
Needham analyst Chad Messer reiterated a Buy rating on NextCure (NXTC – Research Report) today and set a price target
NextCure Reports Fourth Quarter and Full Year 2019 Financial Results
09:00pm, Thursday, 12'th Mar 2020
BELTSVILLE, Md., March 12, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.
Cowen likes Amarin in premarket analyst action
01:47pm, Monday, 02'nd Mar 2020
Akero Therapeutics (NASDAQ:AKRO) initiated with Buy rating and $33 (52% upside) price target at H.C. Wainwright.Amarin (NASDAQ:AMRN) initiated with Outperform rating and $23 (57% upside) price target
NextCure to Present at the 40th Annual Cowen Health Care Conference
01:05pm, Tuesday, 25'th Feb 2020
NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
NextCure to Present at 9th Annual SVB Leerink Global Healthcare Conference
01:05pm, Tuesday, 18'th Feb 2020
NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech
08:12pm, Tuesday, 14'th Jan 2020
Michael Richman, right, is shown here with Sol Langermann at Amplimmune before that company's 2013 sale. Now at NextCure, Richman is CEO, and Langermann is chief scientific officer.
NextCure to Present at the 38th Annual J.P. Morgan Healthcare Conference
09:10pm, Monday, 06'th Jan 2020
BELTSVILLE, Md., Jan. 06, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.
3 Healthcare Stocks With 100% Street Support
10:05am, Sunday, 22'nd Dec 2019
Getting everyone on board isn’t always easy. Whether out at a restaurant ordering a shared platter with friends, or choosing a song from a playlist, it can be challenging to reach an agreement with
Is NextCure, Inc. (NXTC) A Good Stock To Buy ?
11:11am, Monday, 16'th Dec 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks a
NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference
01:05pm, Tuesday, 26'th Nov 2019
NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
NextCure Announces Closing of Public Offering
09:05pm, Tuesday, 19'th Nov 2019
BELTSVILLE, Md., Nov. 19, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.
